CCR2 CyTaC Molecules for Selective Antibody-Recruited Cell Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-based therapeutics suffer from bioavailability issues, high cost, thermal instability, and complex manufacturing, while small molecule therapeutics lack selectivity and have off-target effects, necessitating improved therapeutic approaches for targeting pathogenic cells.
Innovation Solution
Development of heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs), which bind to a target cell-surface protein and an exogenous antibody, utilizing a divalent linker to enhance antibody-dependent cell cytotoxicity (ADCC) against CCR2-expressing cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-based therapeutics are used to target pathogenic cells, then selectivity and immune control are improved, but bioavailability, thermal stability, and manufacturing complexity worsen
Solution Approach 1:
The patent segments the antibody therapeutic into two separate components: a small molecule binder that provides target selectivity and an antibody fragment that provides immune control. This segmentation allows each component to be optimized independently, reducing manufacturing complexity while maintaining the functional benefits of full antibodies.
Solution Approach 2:
The patent introduces a small molecule binder as an intermediary between the target cell and the immune system. This intermediary binds to the target cell surface protein with high selectivity and recruits the antibody fragment to mediate immune responses, thereby reducing the need for complex full-antibody manufacturing while maintaining therapeutic effectiveness.
2Ease of manufacture
If small molecule therapeutics are used to treat diseases, then affordability and stability are improved, but selectivity and off-target effects worsen
Solution Approach 1:
The patent merges the advantages of small molecule therapeutics (affordability and stability) with the advantages of antibody-based therapeutics (selectivity and immune control) by creating a heterobifunctional molecule that combines a small molecule binder with an antibody fragment. This merging allows the therapeutic to maintain high selectivity while being affordable and stable.
Solution Approach 2:
The patent creates a composite therapeutic molecule that combines a small molecule binder (providing affordability and stability) with an antibody fragment (providing selectivity and immune control). This composite structure allows the therapeutic to exhibit properties of both components, achieving high selectivity without sacrificing affordability.
3Reliability
If full antibody therapeutics are used, then immune control and target specificity are improved, but bioavailability and thermal stability worsen
Solution Approach 1:
The patent extracts only the essential immune control function from the full antibody by using an antibody fragment (such as the Fc region) instead of the complete antibody structure. This extraction removes the portions of the antibody that contribute to thermal instability and poor bioavailability while retaining the immune control functionality.
Solution Approach 2:
The patent uses a small molecule binder instead of a full antibody, which is more stable and has better bioavailability. The small molecule acts as a temporary recruiter that brings the antibody fragment to the target site, allowing the therapeutic to function effectively without requiring the stability and longevity of a full antibody.
Data Source
AI summary
The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.